Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

60 Degrees Pharmaceuticals Inc SXTP

Healthcare
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.


NDAQ:SXTP - Post by User

60 Degrees Pharmaceuticals Inc > SXTP....early a.m runner up on no News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(72)
•••
Post by Iseneschalon Jul 19, 2024 8:36am
54 Views
Post# 36139691

SXTP....early a.m runner up on no News

SXTP....early a.m runner up on no NewsThe Market Maker is calling all the Retail Chasers to get on board.....because he has lots of paer to flog to them at inflated prices just so he can short the financing to the insuspected.

Currently trading in the PM open at $0.49

Go ahead.....I dare ya!

Here is the reason:

https://www.sec.gov/Archives/edgar/data/1946563/000121390024061077/ea0207231-s3_60degrees.htm

And it's Effective!!!! 

https://www.sec.gov/edgar/browse/?CIK=0001946563


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities